Corcept Therapeutics Incorporated (CORT) News
Follow Corcept Therapeutics Incorporated (CORT) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 26 public stories across 8 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Healthcare ETF Gains 2.7% as S&P 500 Is Nearly Flat
The State Street Health Care Select Sector SPDR ETF rose 2.7% on Thursday while the S&P 500 was nearly flat, according to Barron's.
EQUITY | Oct 15, 2026, 06:14 PM UTC
L
Corcept Therapeutics' Sean Maduck to Resign as President of Corcept Endocrinology, to Serve as Consultant
Corcept Therapeutics announced that Sean Maduck will resign as President of Corcept Endocrinology effective October 1, 2026, and will provide consulting services to the company through a one-year agreement.Original SEC F
REGULATION | Sep 23, 2026, 12:24 PM UTC
L
CORT - Corcept Announces Planned Leadership Transition
CORT - Corcept Announces Planned Leadership Transition
NEWS | Sep 23, 2026, 12:08 PM UTC
L
Corcept Therapeutics: Justin Gunn to Succeed Maduck, Assume New Responsibilities Starting Oct 1 >CORT
Corcept Therapeutics: Justin Gunn to Succeed Maduck, Assume New Responsibilities Starting Oct 1 >CORT
NEWS | Sep 23, 2026, 12:02 PM UTC
L
Corcept Therapeutics Announces Retirement of Sean Maduck, Pres Its Endocrinology Division
Corcept Therapeutics Announces Retirement of Sean Maduck, Pres Its Endocrinology Division
NEWS | Sep 23, 2026, 12:01 PM UTC
L
Corcept Therapeutics Incorporated (CORT) Taps Justin Gunn To Lead Endocrinology
Corcept Therapeutics said President of its Endocrinology division Sean Maduck will retire and stay on as a senior commercial advisor; Justin Gunn will assume the role effective Oct. 1 and join the Executive Team, reporti
NEWS | Sep 23, 2026, 12:01 PM UTC
L
Corcept Announces Planned Leadership Transition
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modula
NEWS | Sep 23, 2026, 12:00 PM UTC
L
CORT - Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)
CORT - Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)
NEWS | Sep 18, 2026, 12:11 PM UTC
M
S&P SmallCap 600 to drop Shenandoah, Verra, Matthews, Franklin BSP
Shenandoah Telecommunications, Verra Mobility, Matthews International and Franklin BSP Realty to leave the S&P SmallCap 600.
EQUITY | Sep 04, 2026, 09:41 PM UTC
M
Brinker International and Corcept Therapeutics to move to S&P MidCap 40
Brinker International and Corcept Therapeutics are moving from S&P SmallCap 600 to S&P MidCap 40.
EQUITY | Sep 04, 2026, 09:30 PM UTC
H
Stock Market Today: Microsoft Ignites Chip Rebound as SanDisk Jumps 24%
U.S. equities clawed back Wednesday’s post-Fed losses by midday Thursday, with a blowout cloud print from Microsoft Corp. (NASDAQ: MSFT ) reviving the artificial intelligence trade and dragging beaten-down semiconductor
EARNINGS | Jul 30, 2026, 05:29 PM UTC
H
Lam Research, Xerox, FormFactor, Microsoft And Other Big Stocks Moving Higher On Thursday
U.S. stocks were higher, with the Dow Jones index gaining around 300 points on Thursday. Shares of Lam Research Corp (NASDAQ: LRCX ) rose sharply after the company reported better-than-expected fourth-quarter financial r
EARNINGS | Jul 30, 2026, 02:23 PM UTC
L
CORT highs +29% after results yesterday
CORT highs +29% after results yesterday
EARNINGS | Jul 30, 2026, 02:15 PM UTC
L
Corcept Therapeutics shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 sale
Corcept Therapeutics shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 sales guidance above estimates. Also, HC Wainwright raised its price target on the s
EARNINGS | Jul 30, 2026, 01:24 PM UTC
L
CORT Raise PT to $165 from $88 after better Q3 results @ Piper
CORT Raise PT to $165 from $88 after better Q3 results @ Piper
EARNINGS | Jul 30, 2026, 01:17 PM UTC
H
Premarket Gainers: NUWE +100%
NUWE leads premarket gainers
EQUITY | Jul 30, 2026, 09:32 AM UTC
H
Why Microsoft Shares Are Trading Higher By 8%; Here Are 20 Stocks Moving Premarket
Shares of Microsoft Corp (NASDAQ: MSFT ) rose sharply in pre-market trading after the company reported better-than-expected fourth-quarter financial results. Microsoft reported fourth-quarter revenue of $90.01 billion, u
EARNINGS | Jul 30, 2026, 08:30 AM UTC
L
Corcept Therapeutics (CORT) Stock Soars 22% After Hours: Here's What You Need To Know
Corcept Therapeutics Incorporated (NASDAQ: CORT ) shares soared 21.95% to $113.35 after the bell on Wednesday following the announcement of second-quarter results, where both revenue and earnings per share topped analyst
EARNINGS | Jul 30, 2026, 06:48 AM UTC
H
PRCH +20%, CORT +18.3%, BOOM +17.3%, FORM +16.4%, SBUX +10.2%, FTNT +9.4%, BHE +9.3%, LUNG +8.8%, LRCX +7.6%, CMG +7.1%, GKOS +7%, GFL +5.7%
PRCH +20%, CORT +18.3%, BOOM +17.3%, FORM +16.4%, SBUX +10.2%, FTNT +9.4%, BHE +9.3%, LUNG +8.8%, LRCX +7.6%, CMG +7.1%, GKOS +7%, GFL +5.7%, RGR 4.8%, MOD +3.9%, ICLR +3.8%, ST +3.6%, MAX +2.6%, EQIX +2.4% after results
EARNINGS | Jul 29, 2026, 08:27 PM UTC
L
CORT Corcept Therapeutics RESULTS: Q2, Q2 EPS $0.36, Q2 REV $256.147M, Q2 Net Income $42.987M
CORT Corcept Therapeutics RESULTS: Q2, Q2 EPS $0.36, Q2 REV $256.147M, Q2 Net Income $42.987M
EARNINGS | Jul 29, 2026, 08:22 PM UTC
L
CORT - Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
CORT - Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
EARNINGS | Jul 29, 2026, 08:12 PM UTC
L
Corcept Therapeutics Raises FY2026 Sales Guidance from $950.000M-$1.050B to $1.100B-$1.200B vs $1.008B Est
Corcept Therapeutics (NASDAQ: CORT ) raises FY2026 sales outlook from $950.000 million-$1.050 billion to $1.100 billion-$1.200 billion vs $1.008 billion estimate.
EARNINGS | Jul 29, 2026, 08:09 PM UTC
H
serial disappointer risk (missed last 2 qtrs) in EPS reporters tonight and tomorrow morning - FTAI, AWK, CORT, CP, SCI, AGI, VKTX, MTH, NEU,
serial disappointer risk (missed last 2 qtrs) in EPS reporters tonight and tomorrow morning - FTAI, AWK, CORT, CP, SCI, AGI, VKTX, MTH, NEU, PPC, PI, UFPI, PFSI, BBT, FCPT, EFOR, RYZ, CVLG, FBRT, RGR, GBFH, SPOK, CMTG, F
EARNINGS | Jul 29, 2026, 05:04 PM UTC
L
CORT Downgrade from Peerperform to Underperform W/$50.00 PT at Wolfe Research
CORT Downgrade from Peerperform to Underperform W/$50.00 PT at Wolfe Research
EQUITY | Jul 27, 2026, 12:07 PM UTC
L
CORT downgraded from Peer Perform to Underperform W/ $50 PT @ Wolfe
CORT downgraded from Peer Perform to Underperform W/ $50 PT @ Wolfe
EQUITY | Jul 27, 2026, 11:11 AM UTC
L
Largest premium to VWAP ACN (+3.25%) CRWD (+3.11%) PLTR (+3.02%) CORT (+2.78%) KD (+2.67%) WDAY (+2.54%) CRM (+2.4%) INTU (+2.33%) OKTA (+2.
Largest premium to VWAP ACN (+3.25%) CRWD (+3.11%) PLTR (+3.02%) CORT (+2.78%) KD (+2.67%) WDAY (+2.54%) CRM (+2.4%) INTU (+2.33%) OKTA (+2.29%) PANW (+2.25%) (Russell 1000 names)
EQUITY | Jul 14, 2026, 05:28 PM UTC